Wei Rui, Yang Ding-yi, Jiang Wu-zhong, Dai You-yi, Wan Long-yun, Yang Zhen
Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):391-4.
To evaluate the efficacy and toxicity of Yanshu injection (a compound Chinese traditional medicine from Sophora flauescens Ait) combined with concomitant radiochemotherapy in patients with stage III nasopharyngeal carcinoma.
Sixty patients with stage III nasopharyngeal carcinoma were randomized into Yanshu group and control group (n = 30, each). Patients in the Yanshu group received Yanshu injection in addition to intensity modulated radiation therapy (IMRT) and concomitant chemotherapy, and those in the control group were treated with IMRT and concurrent chemotherapy.
The 1-year, 2-year, 3-year and 4-year overall survival rates were 100%, 93.3%, 86.7%, 80.0% for Yanshu group, and 96.7%, 90.0%, 83.3%, 76.7% for the control group, respectively, with no significant difference between the two groups (P = 0.565). The 1-year, 2-year, 3-year and 4-year progression-free survival rates were 96.7%, 90.0%, 83.3%, 70.0% for Yanshu group, and 90.0%, 86.7%, 76.7%, 66.7% for control group, respectively, with no significant difference (P = 0.554). However, the reaction of mucosa of oral cavity, myelosuppression and thrombocytopenia in the Yanshu group were significantly lower than that in the control group (P < 0.05). The quality of life of the patients in the Yanshu group was significantly higher than that in the control group (P < 0.05).
Yanshu injection combined with radiochemotherapy in patients with stage III nasopharyngeal carcinoma show a good efficacy and can reduce the side effects of radiochemotherapy of nasopharygeal carcinoma, and improve the quality of life of the patients.
评价岩舒注射液(一种来源于苦参的复方中药)联合同步放化疗治疗Ⅲ期鼻咽癌患者的疗效及毒性。
将60例Ⅲ期鼻咽癌患者随机分为岩舒组和对照组,每组30例。岩舒组患者在调强放射治疗(IMRT)及同步化疗基础上接受岩舒注射液治疗,对照组患者接受IMRT及同步化疗。
岩舒组1年、2年、3年及4年总生存率分别为100%、93.3%、86.7%、80.0%,对照组分别为96.7%、90.0%、83.3%、76.7%,两组间差异无统计学意义(P = 0.565)。岩舒组1年、2年、3年及4年无进展生存率分别为96.7%、90.0%、83.3%、70.0%,对照组分别为90.0%、86.7%、76.7%、66.7%,差异无统计学意义(P = 0.554)。然而,岩舒组口腔黏膜反应、骨髓抑制及血小板减少情况明显低于对照组(P < 0.05)。岩舒组患者生活质量明显高于对照组(P < 0.05)。
岩舒注射液联合放化疗治疗Ⅲ期鼻咽癌患者疗效良好,可减轻鼻咽癌放化疗的副作用,提高患者生活质量。